Recent News

Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 Clinical Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain

Read Press release

Centrexion Therapeutics Announces Two CNTX-4975 Presentations at the 2018 American College of Rheumatology Annual Meeting

Read Press release

Centrexion Therapeutics Appoints Andrew Partridge as Executive Vice President, Chief Commercial Officer

Read Press release

Centrexion Therapeutics Announces CNTX-4975 Data Presentation at PAINWeek 2018 National Conference

Read Press release

Centrexion Therapeutics Appoints Dan Mendelson to its Board of Directors

Read Press release

Centrexion Therapeutics Appoints Financial Executive Nick Harvey as Chief Financial Officer

Read Press release

Centrexion Therapeutics Appoints Veteran Healthcare Innovator Joseph R. Swedish to its Board of Directors

Read Press release

Centrexion Therapeutics Announces CNTX-4975 and CNTX-6970 Clinical Data Presentations at the 34th Annual American Academy of Pain Medicine Meeting

Read Press release

Centrexion Therapeutics to Present CNTX-4975 Clinical Data at the American Academy of Orthopaedic Surgeons 2018 Annual Meeting

Read Press release

Centrexion Therapeutics Announces First Patient Dosed in Phase 3 Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain

Read Press release

Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Knee Osteoarthritis Pain

Read Press release

Centrexion Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference

Read Press release

Centrexion Therapeutics Raises $67 Million; Launching Phase 3 Program for CNTX-4975 in Knee Osteoarthritis Pain in 2018

Read Press release

Centrexion Therapeutics Announces Multiple Data Presentations on CNTX-4975 at the American College of Rheumatology Annual Meeting 2017

Read Press release

Centrexion Therapeutics to Present Clinical Data from Pipeline of Chronic Pain Treatments at the 11th Annual Pain and Migraine Therapeutics Summit

Read Press release

Centrexion Therapeutics to Present 6-Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at PAINWeek 2017

Read Press release

Centrexion Therapeutics to Present Phase 2b Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Morton’s Neuroma at the American Podiatric Medical Association 2017 Annual Scientific Meeting

Read Press release

Centrexion Therapeutics Provides Updates and Advancements for Pipeline of Chronic Pain Treatments

Read Press release

Centrexion Therapeutics Names Shawn Tomasello to its Board of Directors

Read Press release

Centrexion Therapeutics Announces New 6-Month Data Demonstrating Significant and Durable Pain Relief with CNTX-4975 for Treatment of Moderate to Severe Knee Osteoarthritis Pain

Read Press release

Centrexion Therapeutics Announces Oral Presentation of Six Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at the Annual European Congress of Rheumatology (EULAR 2017)

Read Press release

Centrexion Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference

Read Press release

Centrexion Therapeutics to Present Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at European Federation of National Associations of Orthopaedics and Traumatology’s 2017 Annual Congress

Read Press release

Centrexion Therapeutics to Present Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Morton’s Neuroma and Knee Osteoarthritis at American Pain Society 2017 Annual Scientific Meeting

Read Press release

Centrexion Therapeutics to Present Data on CNTX-4975 from the Treatment of Knee Osteoarthritis Pain at IX SIMPAR-ISURA

Read Press release

Centrexion Therapeutics to Present Late-Breaking Poster at the 33rd Annual American Academy of Pain Medicine Meeting

Read Press release

Centrexion Therapeutics to Present at the 19th Annual BIO CEO & Investor Conference

Read Press release

Centrexion Therapeutics Announces Highly Statistically Significant Topline Results from Phase 2b Study of CNTX-4975 in Patients with Knee Osteoarthritis Pain

Read Press release

Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Morton’s Neuroma

Read Press release

Centrexion Therapeutics Expands Pain Pipeline with Acquisition of Three New Analgesic Candidates from Boehringer Ingelheim

Read Press release